The HDGF Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal population of A-549 cells with targeted disruption of the HDGF gene. This product provides researchers with a genetically heterogeneous knockout model to study the loss-of-function effects of HDGF in a human lung adenocarcinoma background. The polyclonal format captures a spectrum of editing events across the cell population, avoiding the biases of single-cell clonal isolation while preserving the overall knockout phenotype.
The host cell line A-549 was originally derived from the lung adenocarcinoma of a 58-year-old Caucasian male and serves as a widely utilized model for type II alveolar epithelium and non-small cell lung cancer (NSCLC). These adherent epithelial cells exhibit properties characteristic of lung adenocarcinoma, including anchorage-independent growth and tumorigenicity in immunodeficient mice, making them a relevant system for investigating lung cancer biology and therapeutic interventions.
HDGF functions as a paracrine mitogen and intracrine transcriptional repressor. Upstream activators include hypoxia (HIF-1??), EGF, serum, and inflammatory cytokines (TNF-??, IL-6). Following nucleolin-dependent internalization, HDGF associates with HDGFRP2/3 and karyopherin ??2, facilitating nuclear translocation. HDGF then promotes Ras-MAPK/ERK and PI3K/Akt signaling, resulting in ERK and Akt phosphorylation, which in turn activate NF-??B and ??-catenin. These transcription factors drive expression of cyclin D1, c-Myc, survivin, Bcl-2, VEGF, and MMP2, while HDGF-mediated recruitment of p300 and interactions with Smad2/3 repress other gene targets. Through these mechanisms, HDGF sustains proliferation, survival, and angiogenesis in A-549 cells.
Disruption of HDGF in this polyclonal A-549 population ablates nucleolin-dependent ERK and Akt activation, leading to downregulation of cyclin D1, Bcl-2, and VEGF. This impairs cell cycle progression, survival, and angiogenic potential, revealing the essential role of HDGF in maintaining the transformed phenotype. The model enables dissection of HDGF-dependent growth mechanisms and crosstalk with hypoxia/inflammatory signals in NSCLC progression and drug resistance.
This knockout population enables diverse assays: western blot and RT-qPCR for pathway verification, RNA-seq for transcriptomic profiling, MTT/MTS and colony formation for proliferation, wound healing and transwell assays for migration and invasion, Annexin V for apoptosis, tube formation for angiogenesis, and drug sensitivity testing. Applications include lung cancer oncogene studies, growth factor signaling research, tumor microenvironment modeling, and target validation. For further details or inquiries about this product, please contact Ascent Research.
